Mark Mascolini reports on a new study comparing statin indications in male veterans with HIV, HCV or both with three sets of cholesterol guidelines and examining why almost one-third of statin-eligible veterans were not getting the drugs.
Hepatitis C infection proved to be the prime driver of non-AIDS events in a prospective study of 320 HIV patients in Spain who maintained a low or undetectable viral load without antiretroviral therapy.
A reference chart that lists all the HCV treatments currently and soon to be available.
Treatment for HCV can be expensive, but the good news is that help is out there. Many of the pharmaceutical companies have a patient assistance program (PAP) to help uninsured and underinsured people cover all or part of the costs of their drug.
With over 30,000 infections reported in 2014 -- at least 70% of which occurred among people who inject drugs (PWID) -- and all the challenges that can come with HCV prevention, it can sometimes feel like infection is inevitable in people who inject d...
HELP-4-HEP help4hep.org 877-435-7443 (toll-free) National hepatitis C support line staffed by trained peer counselors. Health education, resources, referrals for testing and treatment, and emotional support. Monday-Friday, 9am-7pm ET.
HCV Advocate h...
Combinations of two or three hepatitis C virus direct-acting antiviral drugs taken for 8-24 weeks can cure more than 90% of people treated. However, this breakthrough in clinical medicine comes at a cost.
To investigate the issue of reinfection, researchers at the Vancouver Infectious Disease Clinic reviewed the medical records of several hundred people who had been treated and cured of HCV. They found that cases of reinfection were very low.
Sofosbuvir + Velpatasvir (Epclusa) -- Improvements in Quality of Life, Energy and Emotional and Mental Health
Researchers found that among participants who received sofosbuvir + velpatasvir (Epclusa), aspects of mental health assessed began to improve significantly by the fourth week of the study.
Large Review From Three French Studies Finds No Link Between Use of DAAs and Recurrence of Liver Cancer
To cast clarity on the possible association between the use of DAAs and the risk for the development or recurrence of liver cancer, researchers in France who were interested in assessing risks for liver cancer conducted a large review of three prospe...